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Elaﬁn is a serine protease inhibitor produced by epithe-
lial and immune cells with anti-inﬂammatory properties. 
Research has shown that dysregulated protease activity 
may elicit proteolytic cleavage of elaﬁn, thereby impair-
ing the innate immune function of the protein. The aim 
of this study was to generate variants of elaﬁn (GG- and 
QQ-elaﬁn) that exhibit increased protease resistance 
while retaining the biological properties of wild-type (WT) 
elaﬁn. Similar to WT-elaﬁn, GG- and QQ-elaﬁn variants 
retained antiprotease activity and susceptibility to trans-
glutaminase-mediated ﬁbronectin cross-linking. However, 
in contrast to WT-elaﬁn, GG- and QQ-elaﬁn displayed sig-
niﬁcantly enhanced resistance to degradation when incu-
bated with bronchoalveolar lavage ﬂuid from patients 
with cystic ﬁbrosis. Intriguingly, both variants, particularly 
GG-elaﬁn, demonstrated improved lipopolysaccharide 
(LPS) neutralization properties in vitro. In addition, GG-
elaﬁn showed improved anti-inﬂammatory activity in a 
mouse model of LPS-induced acute lung inﬂammation. 
Inﬂammatory cell inﬁltration into the lung was reduced 
in lungs of mice treated with GG-elaﬁn, predominantly 
neutrophilic inﬁltration. A reduction in MCP-1 levels in 
GG-elaﬁn treated mice compared to the LPS alone treat-
ment group was also demonstrated. GG-elaﬁn showed 
increased functionality when compared to WT-elaﬁn and 
may be of future therapeutic relevance in the treatment of 
lung diseases characterized by a protease burden.
Received 9 February 2014; accepted 22 August 2014; advance online  
publication 30 September 2014. doi:10.1038/mt.2014.162
INTRODUCTION
Mature elafin is a 6 kDa serine protease inhibitor largely generated 
via proteolytic processing of trappin-2 (pre-elafin), primarily by the 
mast cell-derived protease tryptase.1,2 Elafin was originally isolated 
from human bronchial secretions in 1985 by Kramps and Klasen3 
under the name of LMI-5000 and subsequently by Schalkwijk et al.4 
and Wiedow et al.5 in 1990 from human psoriatic skin under the 
name SKALP and elafin, respectively. In addition, elafin has also 
been reported to be expressed by macrophages and neutrophils.6 
Work to date has shown that elafin acts as a multifunctional host 
defence protein with antimicrobial, antiprotease, and immunomod-
ulatory properties.7–12 Elafin expression is upregulated at various 
sites of inflammation by a range of proinflammatory mediators6,13–15 
and may provide protection against neutrophilic proteases.16 Elafin 
is recognized as a potent inhibitor of a restricted set of serine prote-
ases, namely neutrophil elastase (NE) and proteinase-3 (PR3).4,5,17,18
Trappin-2 and elafin have a number of transglutaminase (TG) 
reactive residues and therefore can be linked covalently to various 
extracellular matrix proteins such as fibronectin by tissue trans-
glutaminases and retain potent antiprotease activity.19–22 Due to 
its cationic nature, it is postulated that trappin-2 displays antibac-
terial properties via disruption of bacterial cell membranes.7,10 In 
addition, it has been demonstrated that trappin-2 and mature ela-
fin can bind and neutralize lipopolysaccharide (LPS)23,24 thereby 
suppressing macrophage TNF-α production.23 In human mono-
cytic cells, mature elafin inhibited LPS-induced production of 
monocyte chemotactic protein-1 (MCP-1) and activation of both 
activator protein-1 (AP-1) and nuclear factor κB (NF-κB) via dis-
ruptions to the ubiquitin proteasome pathway.9
In the healthy lung, antiproteases such as trappin-2/elafin are 
present providing the lung with a powerful anti-inflammatory 
screen. However, in diseases such as adult respiratory distress syn-
drome (ARDS), chronic obstructive pulmonary disease (COPD), 
and cystic fibrosis (CF), this protease–antiprotease balance is 
tipped in favor of proteases leading to dysregulated extracellular 
protease activity resulting in lung damage. A number of pathogen 
and host proteases have the ability to cleave elafin.25–28 Increased 
NE activity is present in various respiratory diseases including 
ARDS, COPD, and CF and may overwhelm the protective anti-
protease levels within the lung. Indeed, we have found evidence 
of proteolytic cleavage of elafin by NE in patients with CF with 
established Pseudomonas aeruginosa infection.24 Elevated NE 
levels during Pseudomonas infection in the CF lung also leads to 
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cleavage and inactivation of the related antiprotease secretory leu-
coprotease inhibitor.29 An imbalance in NE and trappin-2/elafin 
levels has also been reported in ARDS and COPD patients with 
secondary bacterial infections.26,30,31
In early 2013, the US Food and Drug Administration (FDA) 
granted elafin orphan drug designation for the prevention of 
inflammatory complications associated with transthoracic esoph-
agectomy.32 However, proteolytic cleavage of elafin could atten-
tuate its anti-inflammatory and antiprotease functions and limit 
the efficacy of elafin in clinical trials in conditions such as ARDS, 
CF, and COPD. To address this, we have synthesized novel vari-
ants of elafin, and we hypothesize that these variants will be more 
resistant to NE cleavage and therefore of significant utility in the 
treatment of pulmonary inflammation in diseases characterized 
by a NE burden.
RESULTS
Recombinant synthesis of elaﬁn variants
As shown in Figure 1, mutations to the coding sequence for mature 
elafin, as denoted by the arrows positioned on the WT-elafin 
sequence, were made at the two previously described NE cleavage 
sites in order to generate the GG- and QQ-elafin variants.24 For 
GG-elafin, the codons coding for valines at position 5 and 9 of 
the elafin amino acid sequence were mutated to generate glycine 
residues. For QQ-elafin, the codons coding for valines at position 
5 and 9 of the elafin amino acid sequence were mutated to gen-
erate glutamine residues. These residues were selected as elastase 
cleavage after glycine and glutamine is rare (MEROPS database). 
Neither amino acid substitution had any effect on the isolelectric 
point and net charge of the protein.
Determination of protease inhibition properties of 
the elaﬁn variants
As shown in Table 1, the Ki of both mutated elafin variants (GG 
and QQ) against human NE and PR3 were very closely matched 
to that of WT-elafin. Similarly, addition of equimolar amounts 
of each elafin molecule (WT, GG, and QQ) to NE resulted in a 
significant reduction (P < 0.01) in the turnover of NE substrate 
compared to NE alone (data not shown) indicating effective 1:1 
stoichiometric inhibition of NE by all three elafin proteins.
Western blot analysis of recombinant elaﬁn 
incubated with CF bronchoalveolar lavage ﬂuid and 
NE
To compare the proteolytic susceptibility of GG- and QQ-elafin 
to WT-elafin, we incubated the three elafin proteins with pooled 
Pseudomonas-positive CF bronchoalveolar lavage fluid (BALF) 
over a time period of 0, 2, and 8 hours, and the cleavage prod-
ucts were assessed by western blot analysis (Figure 2a). WT-elafin 
was rapidly cleaved by CF BALF as denoted by the presence of a 
double band at 2 hours which was almost completely degraded 
by 8 hours. In contrast, GG-elafin was completely resistant to 
cleavage by Pseudomonas-positive CF BALF even after 8 hours of 
incubation. There was some evidence of cleavage of QQ-elafin by 
CF BALF, although there was still a significant portion of intact 
QQ-elafin present after 8 hours. The susceptibility of the elafin 
variants to proteolysis by NE was also compared (Figure 2b). 
Similar to the BALF results in Figure 2a, WT-elafin was rapidly 
cleaved by NE, whereas GG- and QQ-elafin remain relatively 
intact over the course of the experiment. However, following the 
60 minutes of incubation, GG-elafin exhibited enhanced resis-
tance to cleavage when compared to QQ- and WT-elafin. Overall, 
these data indicate that the GG-elafin variant is more resistant to 
proteolytic cleavage when compared to QQ- and WT-elafin.
LPS binding and transglutaminase-mediated cross-
linking activity of the elaﬁn variants
Elafin can interact with the LPS of Gram-negative bacteria and 
modulate cellular responses after LPS stimulation.9,23,24 Therefore, 
the ability of the elafin variants to bind and neutralize LPS were 
investigated. As illustrated in Figure 3a, QQ-elafin variant 
retained the highest LPS-binding ability when compared to the 
WT- and GG-elafin. GG-elafin also bound to LPS substantially 
more than the WT-elafin, although not to the same extent as the 
QQ-elafin variant. These findings suggest that the introduction 
of mutations in the GG- and QQ-elafin variants enhances the 
LPS binding activity of both molecules compared to WT-elafin. 
As mentioned previously, elafin can be cross-linked to extracel-
lular matrix proteins such as fibronectin via the action of TG.19–22 
GG-elafin exhibited comparable binding to fibronectin when 
compared to WT-elafin in the presence of the TG (Figure 3b). 
Figure 1 Mutation of neutrophil elastase cleavage sites in recombinant mature elaﬁn. Neutrophil elastase (NE) cleavage sites were previously 
identiﬁed in human mature elaﬁn, and the positions are indicated by the arrows at Val5-Lys6 and Val9-Ser10 (ref. 24). The cleavage sites were 
mutated to Gly5-Lys6 and Gly9-Ser10 for the GG-elaﬁn variant and to Gln5-Lys6 and Gln9-Ser10 for the QQ-elaﬁn variant. The mutations are indi-
cated by underlined bold type letters.
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Furthermore, the QQ-elafin variant demonstrated a significant 
increase in binding to fibronectin when compared to WT-elafin 
(P < 0.05). A similar trend was also observed when compared to 
GG-elafin; however, this was found to be nonsignificant.
Effect of elaﬁn variants on LPS-challenged U937 
monocytic cells
Peripheral blood monocytes (PBMs) and U937 monocytic cells 
were pretreated with WT-elafin and each elafin variant (10 μg/ml) 
prior to LPS stimulation. Secreted IL-8 levels in cell-free super-
natants were quantified by enzyme-linked immunosorbent assay 
(ELISA). PBMs (Figure 4a) and U937s (Figure 4b) pretreated 
with GG-elafin secreted significantly lower levels of IL-8 com-
pared to LPS alone stimulated controls. Furthermore, although 
WT-elafin and QQ-elafin decreased LPS-induced IL-8 release 
from PBMs and U937s, this was not significant suggesting that 
the GG-elafin variant has augmented anti-inflammatory proper-
ties over the parental molecule. Given the preservation of bind-
ing capabilities to extracellular matrix proteins and LPS, and also 
the increased resistance to proteolytic cleavage, GG-elafin was 
selected for further validation experiments in vivo.
Effect of GG-elaﬁn on acute pulmonary inﬂammation 
in vivo
Leading on from the in vitro studies which demonstrated sig-
nificant anti-inflammatory properties of GG-elafin compared to 
WT-elafin, the effects of WT- and GG-elafin in an in vivo model of 
LPS-induced acute lung inflammation were investigated (Figure 
5). Treatment of mice with WT-elafin resulted in a nonsignifi-
cant decrease in inflammatory cell infiltration in response to LPS 
(Figure 5a,b). However, treatment of mice with GG-elafin resulted 
in a significant reduction in LPS-induced neutrophil infiltration 
into the lung when compared to mice treated LPS alone (Figure 
5a; P < 0.01). In order to assess alveolar-capillary barrier perme-
ability induced by LPS, total protein concentrations in BALF were 
Table 1 Comparison of the antiprotease activity of elaﬁn variants
Neutrophil elastase  
Ki (mol/l)
Proteinase 
3 Ki (mol/l)
WT-elafin 8 × 10−11 1.2 × 10−10
GG-elafin 2 × 10−11 5.25 × 10−10
QQ-elafin 3 × 10−11 5.1 × 10−10
WT, wild type.
Figure 2 Susceptibility of elaﬁn variants to cystic ﬁbrosis BALF and 
neutrophil elastase proteolytic cleavage. (a) WT-elaﬁn and elaﬁn vari-
ants were incubated with pooled Pseudomonas-positive BALF collected 
from CF patients for 0, 2, and 8 hours at 37 °C. (b) WT-elaﬁn and ela-
ﬁn variants were incubated with a 3:1 molar excess of neutrophil elas-
tase for 0, 5, 15, and 60 minutes. Samples were subjected to SDS-PAGE 
under nonreducing conditions followed by western blot analysis, and 
elaﬁn was detected using a biotinylated anti-elaﬁn antibody. BALF, bron-
choalveolar lavage ﬂuid; PAGE, polyacrylamide gel electrophoresis; SDS, 
sodium dodecyl sulfate; WT, wild type.
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Figure 3 Relative LPS binding and transglutaminase-mediated cross-
linking properties of elaﬁn variants. (a) Increasing concentrations of 
elaﬁn were analyzed via ELISA to determine the relative LPS-binding 
properties of the elaﬁn recombinant variants. Bound elaﬁn was calcu-
lated as the increase in absorbance at 405 nm (n = 3). (b) The ability of 
elaﬁn variants to cross-link to ﬁbronectin in the presence of guinea pig 
liver transglutaminase was investigated by ELISA. The absorbance read 
at 405 nm reﬂects the cross-linking of elaﬁn to ﬁbronectin (n = 3). *P 
< 0.05; ** P < 0.01. ELISA, enzyme-linked immunosorbent assay; LPS, 
lipopolysaccharide.
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quantified. BALF protein levels were decreased in the WT-elafin 
(not significant) and GG-elafin (Figure 5c; P < 0.01) treated mice 
when compared to that of the LPS alone treated mice. In agree-
ment with in vitro observations (Figure 4), these findings suggest 
that GG-elafin has augmented anti-inflammatory activity over the 
parental WT-elafin molecule.
Given the observed effects of elafin on neutrophilic infiltra-
tion into the lung, chemokine levels in BALF were investigated 
(Figure 6). There was no difference in the levels of KC and MIP-2 
in either the GG-elafin or the WT-elafin treated mice when com-
pared to the LPS alone treated mice (Figure 6a,b). However, there 
was a significant difference in BALF MCP-1 levels from mice 
treated with the GG-elafin compared to those which received the 
LPS treatment alone as shown in Figure 6c (P < 0.01). In con-
trast, mice treated with WT-elafin did not exhibit a significant 
reduction in MCP-1 compared to mice treated with LPS alone 
(Figure  6c). To investigate the effects of elafin on LPS-induced 
protease burden, we measured NE activity in BALF. Overall, NE 
activity was undetectable in the majority of samples. Low turn-
over of substrate was detected only in a number of the LPS sam-
ples (112.5 pmol 7-amino-4-methylcoumarin (AMC)/μg protein 
± 42.7 pmol AMC/μg protein), and no activity was detected in 
the LPS+WT or LPS+GG BAL samples, which suggests that both 
forms of elafin are able to inhibit elastase activity in vivo. As a 
surrogate marker of protease activity, we measured levels of end-
ostatin in the BALF from our study by ELISA. As illustrated in 
Figure 6d, LPS challenge upregulated the levels of endostatin in 
BALF compared to the saline groups. Although both WT- and 
GG-elafin inhibited the generation of endostatin in compari-
son to the LPS alone group, only the GG-elafin was significantly 
Figure 4 Effect of WT-elaﬁn and elaﬁn variants on LPS-induced IL-8 
production by human monocytic cells. (a) PBMs (n = 4 donors) and 
(b) U937s (n = 4) were preincubated with elaﬁn variants followed by 
incubation with Pseudomonas LPS for 16 hours and IL-8 measured in 
supernatants by ELISA. *P < 0.05; **P < 0.01 and ***P < 0.001 versus 
LPS. ELISA, enzyme-linked immunosorbent assay; IL, interleukin; LPS, 
lipopolysaccharide; WT, wild type.
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Figure 5 Elaﬁn-GG attenuates inﬂammatory cell inﬁltration in a LPS-
induced mouse model of acute lung inﬂammation. (a) Differential 
cell counts demonstrated that the decrease in total cell numbers in the 
LPS-treated mice with GG-elaﬁn was attributed to a decrease in neutro-
phil inﬁltration in the lung. (b) Macrophage cell counts demonstrated a 
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with both WT- and GG-elaﬁn. (c) Protein analysis revealed a decrease 
in the presence of protein in BALF collected from lung tissue in mice 
inoculated with LPS and GG-elaﬁn compared to LPS alone treated mice 
and the mice treated with LPS and WT-elaﬁn (n = 4–6). *P < 0.05; **P < 
0.01; ***P < 0.001 versus LPS. BALF, bronchoalveolar lavage ﬂuid; LPS, 
lipopolysaccharide; WT, wild type.
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lower versus LPS alone, which correlates well with our neutrophil 
counts in Figure 6a.
DISCUSSION
Elafin has been previously shown to possess potent inhibitory 
properties toward the neutrophil serine proteases, NE and PR3. 
Given its low molecular weight and potent antiprotease activity, 
it has been postulated that elafin could have potential therapeu-
tic relevance in a number of diseases characterized by a protease 
burden.16,32 However, it has previously been demonstrated by our 
group that elafin is susceptible to proteolysis by NE in the lungs 
of CF patients chronically infected with P. aeruginosa.24 Therefore, 
the development of a more cleavage-resistant elafin molecule 
using directed mutagenesis may offer an attractive strategy for 
the development of elafin as a therapy. The generation of the QQ- 
and GG-elafin variants in this study confirmed enhanced cleav-
age resistance over the native WT-elafin molecule when exposed 
to Pseudomonas-infected CF BALF. Furthermore, the QQ-elafin 
variant demonstrated a significantly increased affinity for fibro-
nectin in the presence of transglutaminase when compared to 
WT-elafin. The increased binding affinity of the QQ-elafin is 
likely due to the introduction of glutamine residues,22 but this 
requires further validation. In addition, we have demonstrated 
increased LPS binding and a reduction in LPS-induced IL-8 pro-
duction in monocytic cells preincubated with GG-elafin com-
pared to WT-elafin. These data led us to consider if GG-elafin 
may have additional anti-inflammatory effects in vivo compared 
to WT-elafin.
With the use of the LPS-induced mouse model of acute lung 
inflammation, we have demonstrated that the GG-elafin variant 
possessed enhanced anti-inflammatory characteristics when com-
pared to the parent WT-elafin molecule as demonstrated by the 
noted reduction in inflammatory cells within the lungs, in par-
ticular, neutrophils. It is acknowledged that neutrophilic influx 
characterizes the early stages of acute pulmonary inflammation 
and is associated with disruption of the alveolar-capillary barrier 
and lung tissue damage.33,34 Although a near onefold reduction in 
neutrophilia was observed in the mice receiving LPS+GG elafin 
compared to those receiving LPS alone, this may not be sufficient 
to reduce lung damage in the host. Further studies are required to 
more carefully evaluate the effect of a onefold reduction perhaps 
using more advanced in vivo models of lung damage. NE activity 
as measured using the substrate AAPV-AMC was only detected 
in a number of the LPS alone BALF samples. No turnover of sub-
strate was detected in the LPS+WT or LPS+GG BAL samples, 
which suggests that both forms of elafin are able to inhibit elastase 
activity in vivo. However, given that the turnover of substrate was 
very low, we suspect that the majority of elastase may be present 
on the surface of airway neutrophils.35 We also quantified levels 
of the endostatin which is a COOH-terminal fragment of colla-
gen XVIII that can be generated by elastase and is upregulated in 
the BALF from a human in vivo LPS challenge model and acute 
Figure 6 Effects of elaﬁn variants on murine pulmonary cytokine levels. Levels of (a) KC, (b) MIP-2, (c) MCP-1, and (d) endostatin in BALF from 
mice treated with LPS alone, LPS and WT-elaﬁn, LPS and GG-elaﬁn, saline alone and saline plus GG elaﬁn were determined by ELISA (n = 4–6). *P < 
0.05; ***P < 0.001 versus LPS. BALF, bronchoalveolar lavage ﬂuid; ELISA, enzyme-linked immunosorbent assay; WT, wild type.
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lung injury patients.36,37 Although both WT- and GG-elafin inhib-
ited the generation of endostatin in comparison to the LPS alone 
group, only the GG-elafin was significantly lower compared to 
LPS alone, which correlates well with our neutrophil counts.
It is well documented that the chemokines, KC and MIP-2, play 
key roles in the regulation of neutrophil infiltration into the lung, 
especially in response to various mediators, such as TNF-α and 
LPS. However, in this current investigation, we noted that KC and 
MIP-2 levels remained unaffected in response to elafin treatment. 
However, we have shown that in vivo administration of GG-elafin in 
mice receiving LPS resulted in a significant reduction in MCP-1 lev-
els compared to LPS alone and mice receiving LPS and WT-elafin. 
MCP-1, known to regulate the expression of β2 integrin, is classi-
cally associated as a chemoattractant for monocytes/macrophages, 
and it has been shown to trigger the adhesion of monocytes to 
inflamed pulmonary epithelium.34,38 Additionally, MCP-1 has been 
shown to act as a neutrophil chemoattractant in a number of acute 
and chronic inflammatory models, with recent data suggesting that 
MCP-1 may have a significant and key role to play in neutrophil 
recruitment and infiltration in the lung.38–41 It has also been pro-
posed to indirectly regulate KC and MIP-2 expression during pul-
monary Escherichia coli infection.38 Furthermore, MCP-1 has been 
shown to play an important role in the bacterial clearance, and a 
deficiency of MCP-1 resulted in attenuation of immune cell influx 
as neutrophil and macrophages were reduced in MCP-1−/− mice.38,41
Maus et al.34 reported that the delivery of exogenous MCP-1 
did not lead to alteration of neutrophil influx to the lung. 
However, the coadministration of MCP-1 and low-dose LPS lead 
to an excessive recruitment of neutrophils, with an approximate 
22-fold increase compared to the 8-fold increase of monocytes.34 
The reason for decreased MCP-1 levels in the lungs of mice treated 
with GG-elafin in our study is not clear, but it may be due to the 
enhanced stability of GG-elafin as an NE inhibitor compared to 
WT elafin. NE has previously been shown to upregulate MCP-1 
production by macrophages.42 In addition, small molecule inhibi-
tors of NE have been shown to significantly reduce MCP-1 levels 
in the lungs of mice treated with LPS.43 Therefore, the enhanced 
stability of GG-elafin compared to WT-elafin may help reduce the 
NE burden more effectively and impact on NE’s ability to upregu-
late MCP-1 production in target cells. Given their similar Ki val-
ues, we would expect both elafin variants to reduce the activity 
of their target proteases such as elastase; however, as indicated 
by the neutrophil counts and the ELISA results, it appears that 
the GG-elafin variant possesses a more potent anti-inflammatory 
activity compared to the WT-elafin due to its increased stability. 
We have previously reported that elafin can inhibit LPS-induced 
production of MCP-1 by monocytic cells via inhibition of LPS-
induced activation of the transcription factors AP-1 and NF-κB.9 
Thus, it is more likely that the greater stability of GG-elafin com-
pared to WT had a more significant effect on LPS-induced expres-
sion of MCP-1 via reduced activation of AP-1 and/or NF-κB.
In conclusion, our demonstration of increased proteolytic resis-
tance of GG-elafin compared to WT-elafin may be beneficial in 
future therapeutic regimes. In late 2013, Phase 2 clinical trials were 
completed for the prevention of myocardial injury upon coronary 
artery bypass surgery within the National Health Service Lothian’s 
Edinburgh Heart Centre with reports expected in early 2014. Given 
the progression of elafin in various clinical trials, we have shown 
that GG-elafin is capable of diminishing the combined problem of 
an excessive neutrophil protease burden as well as increased neutro-
philic inflammation, both of which are characteristic features of a 
number of acute and chronic inflammatory lung conditions.
MATERIALS AND METHODS
Cloning and recombinant synthesis of elaﬁn proteins. Recombinant 
synthesis of mature human WT-elafin was carried out in Pichia pastoris 
as previously described.8,44 In order to generate GG-elafin (V5G/V9G) 
and QQ-elafin (V5Q/V9Q), site-specific mutations were introduced to 
the elafin cDNA by PCR. First, the elafin cDNA template was amplified 
by PCR using forward primers for GG-elafin (5′ ATC CTC GAG AAA 
AGA GCG CAA GAG CCA GGC AAA GGT CCA GGC TCC ACT AAG 
CC-3′) or QQ-elafin (5′ ATC CTC GAG AAA AGA GCG CAA GAG 
CCA CAA AAA GGT CCA CAA TCC ACT AAG CC-3′) and a reverse 
primer (5′-CGA-GCGGCCGC-CCCTCTCACTGGGGAAC-3′) (Eurofins 
Operon), and a blend of PCR enzymes (Expand High Fidelity PCR System; 
Roche, Meylan, France). The cDNA was then cut with XhoI and NotI 
(Thermo Fisher Scientific Biosciences, Villebon sur Yvette, France) and 
ligated into the pPIC9 vector (Invitrogen, Groningen, The Netherlands) 
linearized with the same enzymes. After transformation of competent E. 
coli XL1 blue (Agilent Technologies, Waldbronn, Germany), positive clones 
were screened by PCR, and DNA sequencing was performed to be sure that 
only the two desired mutations were correctly introduced. After SalI diges-
tion, the recombinant pPIC9 vectors were electroporated in the GS115 P. 
pastoris strain, and transformants screened by their capacity to grow on 
histidine-free regeneration dextrose medium. Finally, elafin production was 
performed in BMMY medium (methanol 1%) to select the clones having 
the higher level of elafin secretion.
Puriﬁcation method. Concentrated supernatants of elafin secreting P. pas-
toris cultures were dialysed against 25 mmol/l sodium phosphate, pH 6.0 
(equilibrium buffer) and loaded onto a Source 15S (GE Healthcare Life 
Sciences, Buckinghamshire, UK) cation-exchange column (1.6 × 15 cm) 
equilibrated with equilibrium buffer using an AKTA chromatographic 
system. The column was washed exhaustively with equilibrium buffer to 
remove unbound proteins, and the bound inhibitors were eluted at a flow 
rate of 1 ml/minute with a linear NaCl gradient (0–1 mol/l) in equilibration 
buffer for 40 minutes. The purity of each elafin preparation was assessed 
by high-resolution Tricine sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis45 under nonreducing conditions and Coomassie staining 
(Supplementary Figure S1).
Protease activity assays. The Ki of each elafin (WT, GG, and QQ) was 
evaluated as previously described using human NE and PR3 as the target 
proteases.8,44 To determine stoichiometric inhibition of NE by the elafin 
proteins, equal concentrations of each elafin variant (WT, GG, and QQ) 
were incubated with NE (8.5 × 10−7 mol/l) in incubation buffer (0.1 mol/l 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; pH 7.5; 0.5 mol/l 
NaCl) for 30 minutes at room temperature and then incubated with 50 
μmol/l NE substrate N-Methoxy-Succinyl-Pro-Ala-Ala-Val-7-amino-4-
methylcoumarin (AAPV-AMC) for 30 minutes. Changes in fluorescence 
were monitored at 365/460 nm for excitation/emission and plotted as rela-
tive fluorescence units per minute. BALF NE activity was determined using 
AAPV-AMC (Enzo Life Sciences, Exeter, UK) as described previously.29
Cystic ﬁbrosis bronchoalveolar lavage ﬂuid samples and study approval. 
BALF samples were obtained from five CF patients with chronic P. aeru-
ginosa infection (Ps+) as described previously.29 Clinical information for 
patients is depicted in Table 2. Ethical approval was obtained from the 
institutional review board of the Adelaide and Meath Hospital incorpo-
rating the National Children’s Hospital with all parents providing written 
informed consent prior to participation.
Molecular Therapy vol. 23 no. 1 jan. 2015 29
© The American Society of Gene & Cell Therapy
Characterization of an Improved Elaﬁn Variant
Western blot analysis of recombinant elaﬁn incubated with CF BALF 
and neutrophil elastase. Each elafin variant (WT, GG, and QQ; 50 ng) was 
incubated with 5 μl of pooled Pseudomonas-positive CF BALF in TBS in a 
final volume of 20 μl for 0, 2, and 8 hours at 37 °C as previously described.24 
Alternatively, the elafin variants (100 ng) were incubated with a 3:1 molar 
excess of neutrophil elastase (Elastin Products Company, Owensville, MO) 
in 0.1 mol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 0.5 mol/l 
NaCl, pH 7.5, in a total volume of 20 μl for 0, 5, 15, and 60 minutes at 
37 °C. The reactions were terminated by addition of nonreducing sample 
treatment buffer and boiling at 99 °C for 10 minutes. Samples were sepa-
rated by Tricine sodium dodecyl sulfate–polyacrylamide gel electropho-
resis (17.5%) under nonreducing conditions and transferred onto 0.1 μm 
nitrocellulose membrane (Sigma-Aldrich, Dorset, UK). The membrane 
was blocked for 1 hour at room temperature in 3% bovine serum albumin 
(BSA) in phosphate-buffered saline (PBS) containing 0.1% (v/v) Tween 20. 
Elafin was detected using a biotinylated antielafin antibody (1:500, over-
night at 4 °C; R&D Biosystems, Abingdon, UK). After washing, the mem-
brane was incubated with streptavidin–HRP (1:2,500, 20 minutes at room 
temperature; BioLegend, London, UK), and elafin visualized by chemi-
luminescence (GE Healthcare). Images were captured using the Syngene 
G:Box and GeneSnap software (SynGene, Cambridge, UK).
LPS-binding ELISA. The ability of elafin variants to bind LPS was analyzed 
by ELISA as described previously.24,46 Briefly, Greiner high binding 96-well 
plates were coated with 100 ng/well of P. aeruginosa LPS (Sigma-Aldrich, 
Dorset, UK) for at least 3 hours at 37 °C. The wells were washed three 
times with distilled water before air-drying overnight at room temperature. 
Plates were blocked with 1% BSA in PBS containing 0.1% (v/v) Tween 20 
for at least 1 hour at room temperature. The wells were blocked with 200 
μl/well 1% BSA in PBS for 1 hour at 37 °C. Elafin variants (0–1,000 ng) 
were made up to 100 μl and incubated on the plate for 2 hours at 37 °C. 
After washing, biotinylated anti-elafin antibody was added to the plate 
for 2 hours at room temperature (100 μl/well; 1:100). Plates were again 
washed, and 100 μl of streptavidin-HRP added per well for 30 minutes at 
room temperature. After washing, peroxidase activity was measured by the 
addition of ABTS substrate (Life Technologies, Paisley, UK) and reading 
the absorbance at 405 nm in a microplate reader (Synergy HT using Gen5 
software; BioTek, Bedfordshire, UK).
Transglutaminase mediated cross-linking of elaﬁn variants to ﬁbro-
nectin. Transglutamination reactions were performed as previously 
described22 with minor modifications. Briefly, Greiner high binding 96-well 
plates were coated with 1 mg/ml of human fibronectin (Sigma-Aldrich) in 
0.1 mol/l sodium carbonate buffer (pH 9.5) overnight at 4 °C. The wells 
were washed with PBS, and the free sites were blocked by incubation in 
block buffer (50 mmol/l Tris, 150 mmol/l NaCl2, and 2% TWEEN 20) for 
1 hour at 37 °C. After washing, elafin variants (8.5 × 10–7 mol/l) were added 
with or without guinea pig liver transglutaminase (0.33 U/well; Sigma-
Aldrich) in 50 mmol/l Tris–HCL buffer (pH 7.5), 2 mmol/l CaCl2, and 0.5 
mmol/l dithiothreitol and incubated for 1 hour at 37 °C. After washing, 
biotinylated anti-elafin antibody was added to the plate for 2 hours at room 
temperature (100 μl/well; 1:100). Plates were again washed, and 100 μl of 
streptavidin–HRP added per well for 30 minutes at room temperature. 
After washing, peroxidase activity was measured by the addition of ABTS 
substrate (Life Technologies) and reading the absorbance at 405 nm in a 
microplate reader (Synergy HT using Gen5 software; BioTek).
Cell culture and ELISA. Ethical approval for use of PBMs from buffy 
coat was given by Northern Ireland Blood Transfusion Service. Human 
myelomonocytic U937s were purchased from the American Type Culture 
Collection (Manassas, VA). Both PBMs and U937s were routinely cul-
tured in RPMI 1640 medium supplemented with 10% heat-inactivated 
fetal calf serum (Gibco, Life Technologies), 2 mmol/l l-glutamine, and 
1% (v/v) penicillin/streptomycin (PAA laboratories, Pasching, Austria). 
Cells for experiments were seeded at 5 × 105/ml and were preincubated 
with elafin variants (WT, GG, and QQ; 10 μg/ml) for 1 hour followed by 
incubation with Pseudomonas LPS (Sigma-Aldrich) for 16 hours. Cell-free 
supernatants were stored at −80 °C until required. Levels of human IL-8 in 
PBM and U937 supernatants were quantified using ELISA kits from R&D 
Systems according to manufacturer’s instructions.
Mice. C57Bl/6 female mice were purchased from Charles Rivers 
Laboratories and also bred in-house. Mice aged between 10 and 12 weeks 
were used for in vivo experiments. Housing and experimentation was car-
ried out in accordance with the Animal (Scientific Procedures) Act 1986 
and current guidelines approved by the Queen’s University Ethical Review 
Committee. The animals were maintained on a 12 hour cycle of light fol-
lowed by 12 hour cycle of darkness with free access to chow and water.
Effect of elaﬁn variants on pulmonary inﬂammation in a LPS-induced 
acute lung injury mouse model. Under anesthesia, Pseudomonas LPS 
(0.4 mg/ml; Sigma-Aldrich, Serotype 10, Source strain ATCC 27316) in 
saline and saline alone were intratracheally instilled into the mice (n = 4–6/
group) with the aid of a blunted 24g IV catheter (BD Biosciences, Oxford, 
UK) into the lungs to a final volume of 50 μl. Pseudomonas LPS and saline 
alone were combined with 100 μg of WT- or GG-elafin and instilled as 
described above. After 4 hours, the mice were sacrificed and BALF col-
lected. Briefly, a blunt needle (23 gauge) was inserted through a small 
incision in the upper trachea and tied in place with 3.0 surgical mersilk 
(Ethicon, Livingston, UK). BALF collection was performed by instilling a 
total of 0.8 ml of sterile ice-cold PBS gently into the lungs of each mouse 
with careful aspiration of the fluid. BALF cells were pelleted by centrifuga-
tion at 2,200 rpm for 10 minutes at 4 °C, and cell-free BALF was collected 
and stored at −80 °C until required. BALF cells were resuspended in 100 
μl of PBS, and total cells counts were performed using a hemocytometer.
Differential cells staining and cell counts. Differential cell staining was per-
formed on the cells collected and counted from the BALF. Approximately 
5 × 105 cells were cytospun onto coated cytoslides (Shandon; Thermo 
Scientific) and stained with the Giemsa and May-Grünwald stain (VWR, 
Lutterworth, UK). Briefly, cells were fixed in methanol for 20 minutes and 
allowed to air dry. Slides were immersed in May-Grünwald stain for 8 min-
utes and transferred into PBS for a quick and gentle wash. Slides were then 
immersed into the Giemsa stain for 8 minutes and washed briefly under 
tap water. Excess water was removed, and the slides were allowed to air dry. 
Slides were mounted with aqueous Vectamount media (Vectorlabs, UK), 
sealed with clear nail polish and allow to dry. Cells were visualized using a 
Leica DM5500B microscope and images captured using the image analysis 
Leica AL software (version 3.7, Leica Microsystems, Milton Keynes, UK) 
under ×40 objective lens. Histological cell counts were conducted on each 
slide where at least 400 cells per slide were counted.
BALF protein and cytokine analyses. BALF total protein concentrations 
were determined using the BCA method (Pierce BCA Assay; Fisher 
Scientific UK, Leicestershire, UK). Relative cytokine profiles in BALF 
(n = 4–6/group) from mice treated with LPS alone, LPS + GG-elafin, and 
Table 2 Cystic ﬁbrosis bronchoalveolar lavage ﬂuid patient dataa
CF BALF (n = 5)
Age at BAL, years 14.63 (1.788)
Neutrophil elastase activity, μmol/l 18.00 (3.334)
FEV1 37.6 (6.153)
Total cells/ml 1.308 × 107 (1.213 × 106)
Neutrophils/ml 1.229 × 107 (1.351 × 106)
Macrophage/ml 5.745 × 105 (3.031 × 105)
BALF, bronchoalveolar lavage ﬂuid; CF, cystic ﬁbrosis; FEV1, forced expiratory 
volume in 1 second.
aValues represent mean (SEM).
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LPS + WT-elafin were analyzed for levels of CXCL1/KC, CXCL2/MIP-2, 
and CCL2/MCP-1 using ELISA kits from R&D Systems. Endostatin levels 
were quantified by ELISA (USCN Life Science, Hubei, China). All kits were 
used according to the manufacturer’s instructions.
Statistical analysis. All data were analyzed using GraphPad Prism 5.0 
(GraphPad Software, San Diego, CA) and are reported as mean ± SEM. 
Results are representative of at least n = 3 unless otherwise indicated. 
Means were compared by unpaired t-test, one-way analysis of variance 
(ANOVA with Tukey’s multiple comparison test), or Kruskal–Wallis 
test (with Dunn’s multiple comparison test) as appropriate. P < 0.05 was 
accepted to indicate statistical significance.
SUPPLEMENTARY MATERIAL
Figure S1. Purity of recombinant protein preparations.
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